Cornerstone Capital Management Holdings LLC. raised its position in Corcept Therapeutics Incorporated (NASDAQ:CORT) by 268.4% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 105,000 shares of the biotechnology company’s stock after buying an additional 76,500 shares during the period. Cornerstone Capital Management Holdings LLC. owned 0.09% of Corcept Therapeutics worth $2,025,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Bank of Montreal Can increased its stake in Corcept Therapeutics by 111.2% in the 2nd quarter. Bank of Montreal Can now owns 34,931 shares of the biotechnology company’s stock valued at $413,000 after buying an additional 18,389 shares during the last quarter. Birchview Capital LP increased its stake in Corcept Therapeutics by 58.3% in the 2nd quarter. Birchview Capital LP now owns 95,000 shares of the biotechnology company’s stock valued at $1,121,000 after buying an additional 35,000 shares during the last quarter. California Public Employees Retirement System increased its stake in Corcept Therapeutics by 3.6% in the 2nd quarter. California Public Employees Retirement System now owns 148,200 shares of the biotechnology company’s stock valued at $1,749,000 after buying an additional 5,200 shares during the last quarter. Rhumbline Advisers increased its stake in shares of Corcept Therapeutics by 21.5% during the 2nd quarter. Rhumbline Advisers now owns 87,672 shares of the biotechnology company’s stock worth $1,035,000 after purchasing an additional 15,494 shares during the last quarter. Finally, Prudential Financial Inc. increased its stake in shares of Corcept Therapeutics by 3,409.5% during the 2nd quarter. Prudential Financial Inc. now owns 633,223 shares of the biotechnology company’s stock worth $7,472,000 after purchasing an additional 615,180 shares during the last quarter. Hedge funds and other institutional investors own 64.64% of the company’s stock.

Several equities research analysts have recently issued reports on CORT shares. Piper Jaffray Companies set a $30.00 price target on shares of Corcept Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, October 31st. Zacks Investment Research lowered shares of Corcept Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, October 10th. Stifel Nicolaus started coverage on shares of Corcept Therapeutics in a research note on Thursday, August 31st. They set a “buy” rating and a $20.00 price target for the company. Finally, BidaskClub lowered shares of Corcept Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, December 7th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Corcept Therapeutics currently has a consensus rating of “Buy” and an average price target of $21.00.

In related news, insider Robert S. Fishman sold 8,000 shares of the firm’s stock in a transaction that occurred on Friday, December 8th. The shares were sold at an average price of $16.72, for a total value of $133,760.00. Following the completion of the transaction, the insider now directly owns 8,000 shares of the company’s stock, valued at approximately $133,760. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director G Leonard Baker, Jr. sold 30,000 shares of the firm’s stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $17.59, for a total transaction of $527,700.00. The disclosure for this sale can be found here. 19.20% of the stock is currently owned by company insiders.

Shares of Corcept Therapeutics Incorporated (NASDAQ CORT) opened at $15.80 on Thursday. Corcept Therapeutics Incorporated has a one year low of $6.70 and a one year high of $20.77. The stock has a market cap of $1,800.00, a P/E ratio of 57.07 and a beta of 1.89.

Corcept Therapeutics (NASDAQ:CORT) last issued its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported $0.11 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.13 by ($0.02). Corcept Therapeutics had a return on equity of 58.17% and a net margin of 27.28%. The company had revenue of $42.70 million for the quarter, compared to analysts’ expectations of $41.64 million. During the same quarter in the previous year, the business earned $0.02 EPS. The company’s revenue for the quarter was up 96.8% on a year-over-year basis. analysts forecast that Corcept Therapeutics Incorporated will post 0.47 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Cornerstone Capital Management Holdings LLC. Has $2.03 Million Holdings in Corcept Therapeutics Incorporated (CORT)” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another site, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/12/21/cornerstone-capital-management-holdings-llc-has-2-03-million-holdings-in-corcept-therapeutics-incorporated-cort.html.

About Corcept Therapeutics

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR).

Institutional Ownership by Quarter for Corcept Therapeutics (NASDAQ:CORT)

Receive News & Stock Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related stocks with our FREE daily email newsletter.